Concord Drugs Ltd Share Price Today - Concord Drugs Ltd Stock Price Live NSE/BSE

Concord Drugs Ltd

NSE: BSE: 538965

₹76.77

(3.39%)

Tue, 24 Mar 2026, 07:45 am

MTF 5xInvest in Concord Drugs Ltd with 5x Leverage Buy with MTF

Market Cap0

PE Ratio0

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Concord Drugs Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
74
Net Profit
0.34
P/B
0.91
Sector P/E
31.86
P/E
91.41
EV/EBITDA
12.08
Debt/Equity (Industry)
0.23
Interest Cover (Industry)
9.79
ROCE (Industry)
12.90
RONW (Industry)
12.30
ROE
1
ROCE
4.94
Debt/Equity
0.54
EPS (TTM)
0.57
Dividend Yield
0
Book Value
34.42
Interest Cover
1.34

Analysis

all

Pros

Concord Drugs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Concord Drugs is profitable, therefore cash runway is not a concern.
Concord Drugs is profitable, therefore cash runway is not a concern.
Debt is well covered by operating cash flow (26.1%, greater than 20% of total debt).
Debt is covered by short term assets, assets are 6.2x debt.

Cons

Unable to evaluate Concord Drugs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Concord Drugs's dividend against the top 25% market benchmark as the company has not reported any payouts.
Interest payments on debt are not well covered by earnings (EBIT is 1.4x annual interest expense, ideally 3x coverage).
Concord Drugs's level of debt (42.1%) compared to net worth is high (greater than 40%).
High level of physical assets or inventory.

Financials

No Result Found

Ratios

No Result Found

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	54.39	54.39	54.39	54.39	54.39
FII	0	0	0	0	0
DII	0	0	0	0	0
Public	45.61	45.61	45.61	45.61	45.61
Government	0	0	0	0	0

Technical Analysis

RSI

46.04

MACD

-1.30

50 DMA

77.45

200 DMA

67.75

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	114.43	96.77	87.89	79.11	70.23	61.45	43.79
Fibonacci	96.77	90.03	85.86	79.11	72.37	68.20	61.45
Camarilla	83.86	82.24	80.62	79.11	77.38	75.76	74.14

Pivots Level: Classic

+35.32

114.43

+17.66

96.77

+8.77

87.89

79.11

Pivot Point

LTP: 74.10

-8.89

70.23

-17.66

61.45

-35.32

43.79

Moving Average

SMAEMA

Period

Value

10-EMA
74.45
20-EMA
75.37
30-EMA
76.21
50-EMA
77.06
100-EMA
75.51
200-EMA
68.20

Announcement Date	Purpose	Action
14 Feb 2026	board-meetings	Quarterly Results
13 Nov 2025	board-meetings	Quarterly Results
15 Sept 2025	agm
09 Jul 2025	egm
03 Jul 2025	egm
18 Sept 2024	agm
12 Sept 2023	agm
08 Sept 2022	agm
06 Aug 2022	egm
13 Aug 2021	agm

Peer Comparison

No Result Found

Concord Drugs Ltd

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd

Lupin Ltd

Concord Drugs Ltd About

Concord Drugs is to manufacture licensed drugs based on the formulations approved.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1995

Headquarters

CEO

S Nagi Reddy

Employees

Contact

Website

http://www.concorddrugs.in

concorddrugsltd@gmail.com

Phone

91-40-24036379

Location

Survey No 249 Brahmanapally V, Hayathnagar M, Ranga Reddy, Telangana, 501511

Year	History
1995	Concord Drugs Limited was incorporated as a Limited Company with the Registrar of companies, Andhra Pradesh. Concord Drugs Limited was established to manufacture and market innovative pharmaceutical products.
2005	Concord Drugs Limited established Unit-II or Phase-II at Roorkee, Uttrakhand for manufacturing of Tablets & Capsules.
2015	Concord Drugs Ltd was listed and admitted to dealings on the Exchange in the list of 'DT' Group Securities.

Client Name	Order Side	QTY	Avg Price	Date
PRADEEP KUMAR JAIN	Sell	69944	54.48	04 Jul 2025
GANGA DEVI LOYA	Buy	51655	53.25	03 Jul 2025
PRADEEP KUMAR JAIN	Sell	149164	53.21	03 Jul 2025
GANGA DEVI LOYA	Sell	11555	53.9	03 Jul 2025
GANGA DEVI LOYA	Buy	51571	38.66	30 Jun 2025
LAKSHMI PRASANNA PALLETI	Sell	51994	44.63	15 Jan 2024
MATALIA STOCK BROKING PRIVATE LIMITED	Sell	59398	57.71	29 Dec 2023
MATALIA STOCK BROKING PRIVATE LIMITED	Buy	59398	58.36	29 Dec 2023
LAKHUBHA SOLANKI	Buy	51361	48.1	28 Dec 2023
LAKHUBHA SOLANKI	Sell	51361	51.46	28 Dec 2023

Concord Drugs Ltd News

Concord Drugs Q3FY26 Revenue Jumps 56.5% to ₹1,686.13 Lakhs

Concord Drugs Limited reported strong Q3FY26 results with revenue rising 56.5% to ₹1,686.13 lakhs. Net profit increased to ₹21.52 lakhs from ₹22.19 lakhs in Q3FY25, while nine-month revenue reached ₹4,032.00 lakhs.

17 Feb 2026

co actions results

Concord Drugs reconstitutes Board committees

Concord Drugs Limited reconstituted its Board committees on February 14, 2026, and announced the cessation of Director Ramchandra Reddy Kommula due to completion of term.

14 Feb 2026

stocks

Concord Drugs Secures Orders Worth ₹14.71 Crores

Concord Drugs Limited announces receipt of significant purchase orders totaling ₹14.71 crores from various government entities including TNMSC and DGHS for pharmaceutical products delivery within 45-60 days.

30 Dec 2025

co actions results

Concord Drugs Promoters Acquire Additional Shares Through Preferential Allotment

Three promoters of Concord Drugs Limited - S. Koni Reddy, S. Nagi Reddy, and S Manoj Kumar Reddy - acquired additional shares through preferential allotment on 20 November 2025. The transaction increased the company's equity share capital from 1,00,00,000 to 1,31,75,000 shares, with total diluted share capital reaching 1,52,00,000 shares.

25 Nov 2025

corporate action

Concord Drugs Limited Completes Preferential Allotment of Equity Shares and Convertible Warrants

Concord Drugs Limited's Board approved the allotment of 31,75,000 equity shares at Rs. 36.30 per share raising Rs. 11,52,52,500 and 20,25,000 convertible warrants aggregating Rs. 7,35,07,500. The allotments were made to promoters and public investors on preferential basis, with warrants convertible within 18 months from allotment date.

20 Nov 2025

corporate action

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800